UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041901
Receipt number R000047825
Scientific Title The study of cardiovascular complications in osteogenesis imperfecta in adulthood
Date of disclosure of the study information 2020/09/27
Last modified on 2023/10/18 14:45:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of cardiovascular complications in osteogenesis imperfecta in adulthood

Acronym

The study of cardiovascular complications in osteogenesis imperfecta in adulthood

Scientific Title

The study of cardiovascular complications in osteogenesis imperfecta in adulthood

Scientific Title:Acronym

The study of cardiovascular complications in osteogenesis imperfecta in adulthood

Region

Japan


Condition

Condition

osteogenesis imperfecta

Classification by specialty

Medicine in general Cardiology Endocrinology and Metabolism
Neurology Pediatrics Orthopedics
Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To determine the frequency of cardiovascular complications in adult patients with osteogenesis imperfecta and contribute to improving patient quality of life.

Basic objectives2

Others

Basic objectives -Others

It is known that osteogenesis imperfecta can be complicated by cardiovascular lesions, but there are few detailed studies. In particular, no studies on cerebral vasculature have existed to date. The purpose of this study is to perform an imaging assessment of cardiovascular issues in patients with osteogenesis imperfecta to determine the prevalence and indications for treatment.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

(A) Heart rate and blood pressure
(B) Echocardiography (presence of valvular disease, left ventricular myocardial thickness, left ventricular diameter, left ventricular ejection fraction, aortic valve diameter, Valsalva sinus diameter, ST junction diameter, descending aorta diameter)
(C) Head MRI and MRA (presence of cerebral aneurysm (defined as more than 2 mm) and size). Head MRI includes the evaluation of presence of basilar impression

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

79 years-old >=

Gender

Male and Female

Key inclusion criteria

Patients between the ages of 30 and 79 years old who were diagnosed with osteogenesis imperfecta in a medical institution.

Key exclusion criteria

Patients who have received treatment for either cerebrovascular or cardiac disease. Other patients who are deemed by the investigators to be unsuitable as subjects

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Yoshihiko
Middle name
Last name Kodama

Organization

University of Miyazaki Hospital

Division name

Department of pediatrics

Zip code

889-1692

Address

5200 kihara Kiyotake-cho, Miyazaki

TEL

0985-85-0989

Email

kodamayoshihiko@gmail.com


Public contact

Name of contact person

1st name Yoshihiko
Middle name
Last name Kodama

Organization

University of Miyazaki Hospital

Division name

Department of pediatrics

Zip code

889-1692

Address

5200 kihara Kiyotake-cho, Miyazaki

TEL

0985-85-0989

Homepage URL


Email

kodamayoshihiko@gmail.com


Sponsor or person

Institute

Fukuoka Children's Hospital
AIC Yaesu Clinic

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labor and Welfare

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Clinical Research Network Fukuoka

Address

3-1-1 Maidashi Fukuoka

Tel

092-643-7171

Email

mail@crnfukuoka.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 09 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2019 Year 10 Month 07 Day

Date of IRB

2019 Year 10 Month 07 Day

Anticipated trial start date

2020 Year 09 Month 01 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Enrolling by invitation


Management information

Registered date

2020 Year 09 Month 27 Day

Last modified on

2023 Year 10 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047825


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name